P-III Archives | PharmaShots

BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

May 10, 2019May 15, 2019Tuba Khan

Shots: The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- [...]

Roche Reports Results of Ocrevus (ocrelizumab) in Three P-III Studies for Relapsing and Primary Progressive Multiple Sclerosis

May 8, 2019May 10, 2019Tuba Khan

Shots: The P-III OPERA, ORATORIO and OBOE studies result involves assessing of Ocrevus (ocrelizumab) vs PBO in patients with RMS and PPMS, presented [...]

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

May 8, 2019May 10, 2019Tuba Khan

Shots: The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a [...]

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Two P-III Studies to Treat Low- and High-Frequency Episodic Migraine

May 7, 2019May 10, 2019Tuba Khan

Shots: The P-III EVOLVE-1 and EVOLVE-2 studies result involves assessing of Emgality (galcanezumab-gnlm, 120mg & 240mg) vs PBO in 1,700 patients with low [...]

GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

May 3, 2019May 7, 2019Tuba Khan

Shots: The P-III CAPTAIN study involves assessing of Trelegy Ellipta (FF/UMEC/VI) (100/31.25/25, 100/62.5/25, 200/31.25/25 and 200/62.5/25 mcg) vs Relvar/Breo Ellipta (FF/VI) (100/25 and [...]

Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

May 2, 2019May 3, 2019Tuba Khan

Shots: The P-III COSMIC-313 study involves assessing of Cabometyx (cabozantinib) + Opdivo (nivolumab) + Yervoy (ipilimumab) vs nivolumab+ ipilimumab + PBO in 676 [...]

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

April 26, 2019April 30, 2019Tuba Khan

Shots: The P-III STELLAR 3 study involves assessing of Selonsertib (18mg, 6mg) vs PBO in 802 patients with F3/bridging fibrosis due to NASH [...]

Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer

April 26, 2019April 30, 2019Tuba Khan

Shots: The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in [...]

Teva Discontinues its P-III ENFORCE Study of Fremanezumab for Episodic Cluster Headache

April 24, 2019April 26, 2019Tuba Khan

Shots: The discontinuation of P-III study is due to the inability of Fremanezumab to meet its 1EPs i.e, reduction in weekly number of [...]

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

April 23, 2019April 24, 2019Tuba Khan

Shots: The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying [...]